← Back to guidelines
Cardiology63 papers

3 beta-Hydroxysteroid dehydrogenase deficiency

Last edited: 4/15/2026

Overview

3-beta-hydroxysteroid dehydrogenase (3β-HSD) deficiency encompasses various forms affecting steroid hormone synthesis, leading to diverse clinical presentations including adrenal insufficiency and ambiguous genitalia in males 2.

Diagnosis

  • Clinical Presentation: Alopecia totalis, ichthyosis, and male pseudohermaphroditism in cases of 17β-HSD deficiency 2.
  • Biochemical Testing: Measurement of plasma acylcarnitines and organic acids to assess metabolic control in long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency 1.
  • Genetic Testing: Confirmation through genetic sequencing to identify specific enzyme deficiencies 12.
  • Management

  • Dietary Therapy: Avoidance of fasting and restriction of long-chain fatty acids (LCFA) intake, with increased medium-chain triglycerides (MCT) to reduce plasma hydroxyacylcarnitines 1.
  • Supplementation: Ensure adequate intake of fat-soluble vitamins E and K, and essential fatty acids (linoleic and linolenic acid) 1.
  • Carnitine: No specific correlation noted between carnitine supplementation levels and plasma acylcarnitines; however, monitoring may be considered 1.
  • Special Populations

  • Pediatrics: Dietary management focusing on LCFA restriction and MCT supplementation is crucial for maintaining health in pediatric patients with LCHAD or TFP deficiency 1.
  • Key Recommendations

  • Implement dietary strategies that limit long-chain fatty acid intake and increase medium-chain triglyceride consumption to manage plasma hydroxyacylcarnitines in LCHAD or TFP deficiency (Evidence: Moderate 1).
  • Ensure adequate dietary intake of fat-soluble vitamins E and K, and essential fatty acids to address deficiencies observed in patients (Evidence: Moderate 1).
  • Regular monitoring of plasma acylcarnitine profiles is recommended to assess the effectiveness of dietary interventions in pediatric patients (Evidence: Expert opinion 1).
  • References

    1 Gillingham MB, Connor WE, Matern D, Rinaldo P, Burlingame T, Meeuws K et al.. Optimal dietary therapy of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Molecular genetics and metabolism 2003. link00073-8) 2 Kauschansky A, Shohat M, Frydman M, Rösler A, Greenbaum E, Sirota L. Syndrome of alopecia totalis and 17b-hydroxysteroid dehydrogenase deficiency. American journal of medical genetics 1998. link

    Original source

    1. [1]
      Optimal dietary therapy of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.Gillingham MB, Connor WE, Matern D, Rinaldo P, Burlingame T, Meeuws K et al. Molecular genetics and metabolism (2003)
    2. [2]
      Syndrome of alopecia totalis and 17b-hydroxysteroid dehydrogenase deficiency.Kauschansky A, Shohat M, Frydman M, Rösler A, Greenbaum E, Sirota L American journal of medical genetics (1998)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG